Skip to main content

Table 1 Genotypes and antibiotic susceptibility patterns of CA- & HA-MRSA from children ≤5 years in eastern Uganda

From: CA-MRSA and HA-MRSA coexist in community and hospital settings in Uganda

Isolate #

PVL

mecA

SCCmec

FOX

PEN

TET

ERY

SXT

CHL

GEN

CIP

CLI

RIF

VAN

LZD

MDR phenotype

Spa type

HA-MRSA (n = 21)

 52–1

+

+

I

R

R

R

R

R

R

R

S

S

S

S

S

Yes

 

 1320–1

+

I

R

R

R

R

R

R

R

R

S

S

S

S

Yes

 

 244C-1

+

I

R

R

R

R

R

R

R

S

S

S

S

S

Yes

 

 K1057–1

+

I

R

R

R

S

S

R

R

S

S

S

S

S

Yes

t037

 K264–1

+

+

I

R

R

R

S

S

R

R

S

S

S

S

S

Yes

 

 K284–1

+

I

R

R

R

R

R

R

R

S

S

S

S

S

Yes

 

 K36–1

+

I

R

R

R

R

R

R

S

S

S

S

S

S

Yes

t037

 K370–1

+

I

R

R

R

R

R

R

R

S

S

S

S

S

Yes

 

 K39–1

+

I

R

R

R

R

R

R

R

R

S

S

S

S

Yes

 

 K4834–1

+

I

R

R

R

S

S

R

R

S

S

S

S

S

Yes

t037

 K970–1

+

I

R

R

R

S

I

S

S

I

S

S

S

S

No

t037

 R030–1

+

I

R

R

R

R

R

R

R

R

S

S

S

S

Yes

 

 R10–1

+

I

R

R

R

R

R

R

S

R

S

S

S

S

Yes

t12939

 R110–1

+

+

I

R

R

R

R

R

S

S

S

S

S

S

S

Yes

Unknown

 R19–1

+

I

R

R

R

R

R

R

R

S

S

S

S

S

Yes

 

 R220–1

+

I

R

R

R

R

R

S

R

S

S

S

S

S

Yes

Unknown

 1322–1

+

+

II

R

R

R

R

R

R

R

I

I

S

S

S

Yes

 

 306C-1

+

II

R

R

R

R

R

I

R

S

S

S

S

S

Yes

 

 K911–1

+

II

R

R

R

R

S

R

R

R

S

S

S

S

Yes

 

 R160–1

+

II

R

R

R

R

R

S

S

S

S

S

S

S

Yes

t002

 R17–1

+

III

R

R

R

S

R

S

I

S

S

S

S

S

Yes

t037

 Total +/R HA-MRSA (%)

4 (19)

21 (100)

21 (100)

21 (100)

21 (100)

21 (100)

16 (76.2)

16 (76.2)

15 (71.4)

15 (71.4)

5 (23.8)

0 (0)

0 (0)

0 (0)

0 (0)

20 (95.2)

 

CA-MRSA (n = 21)

 1325–1

+

IV

R

R

R

R

R

R

I

S

S

S

S

S

Yes

Unknown

 1326–1

+

+

IV

R

R

R

R

S

S

S

R

S

S

S

S

Yes

 

 K2240–1

+

IV

R

R

S

S

S

S

S

R

I

S

S

S

No

t4353

 K2810–1

+

IV

R

R

R

R

R

S

S

R

S

S

S

S

Yes

 

 R31B-1

+

IV

R

R

R

R

R

S

R

R

S

S

S

S

Yes

t064

 R310–1

+

IV

R

R

R

R

R

R

R

S

S

S

S

S

Yes

t064

 R33–1

+

+

IV

R

R

R

R

R

R

R

S

S

S

S

S

Yes

t064

 K3700–1

+

IV

R

R

R

S

S

R

R

S

S

S

S

S

Yes

 

 R0100–1

+

IV

R

R

R

R

R

S

S

S

S

S

S

S

Yes

t064

 R02–1

+

IV

R

R

R

R

R

R

S

R

S

S

S

S

Yes

Unknown

 R020–1

+

IV

R

R

S

S

R

R

R

S

S

S

S

S

Yes

 

 R0300–1

+

IV

R

R

R

R

R

R

S

S

S

S

S

S

Yes

 

 R06–1

+

IV

R

R

R

R

R

S

R

S

S

S

S

S

Yes

t064

 R08–1

+

+

IV

R

R

R

R

R

R

R

S

S

S

S

S

Yes

t064

 R18–1

+

IV

R

R

R

R

S

R

S

R

S

S

S

S

Yes

 

 R20–1

+

IV

R

R

I

R

R

R

R

S

S

S

S

S

Yes

t064

 R26A-1

+

IV

R

R

R

R

R

S

S

R

S

S

S

S

Yes

t064

 R040–1

+

V

R

R

R

R

R

R

R

R

S

S

S

S

Yes

 

 K60–1

+

+

V

R

R

R

R

R

S

S

R

S

S

S

S

Yes

 

 K38–1

+

V

R

R

R

R

R

R

R

I

S

S

S

S

Yes

 

 K350C-1

+

+

V

R

R

R

S

S

S

S

R

S

S

S

S

Yes

Unknown

 Total +/R CA-MRSA (%)

5 (24)

21 (100)

21 (100)

21 (100)

21 (100)

18 (85.7)

17 (81)

16 (76.2)

12 (57.1)

10 (47.6)

10 (47.6)

0 (0)

0 (0)

0 (0)

0 (0)

20 (95.2)

 

Grand Total +/R (%)

9 (21.4)

42 (100)

42 (100)

42 (100)

42 (100)

39 (92.9)

33 (78.6)

32 (76.2)

27 (64.3)

25 (59.5)

15 (35.7)

0 (0)

0 (0)

0 (0)

0 (0)

40/42 (95.2)

 
  1. The most prevalent Spa types are presented in boldface font
  2. FOX cefoxitin, PEN penicillin, TET tetracycline, SXT, ERY erythromycin, CHL chloramphenicol, GEN gentamycin, CIP ciprofloxacin, CLI clindamycin, RIF rifampicin, VAN vancomycin, LZD linezolid, MDR multidrug resistant –resistance to three or more classes of antimicrobials; + Positive, − Negative